This is a phase II, multicenter, single arm, open label study of iberdomide, weekly bortezomib and dexamethasone for upfront treatment of transplant ineligible patients with Multiple Myeloma. This study will evaluate efficacy and tolerability of iberdomide, bortezomib and dexamethasone administered in combination. The study will have an induction phase and a maintenance phase.
This study will evaluate efficacy and tolerability of iberdomide, weekly bortezomib and dexamethasone administered in combination.